Knowing more about HER2+ early breast cancer

A diagnosis of HER2* positive (HER2+) breast cancer can be overwhelming. We want to help you learn more about your early breast cancer treatment.

In early breast cancer, the cancer starts in the breast but has not spread to other parts of the body. However, cancer cells may also be in nearby glands called lymph nodes.

PERJETA is a targeted cancer treatment that can be started before surgery (neoadjuvant) and may be started or continued after surgery (adjuvant). It is given in combination with a medication called Herceptin® (trastuzumab) and chemotherapy.

*HER2 stands for human epidermal growth factor receptor 2. The results from a HER2 test are needed to know if your breast cancer is HER2+.

Learn about PERJETA + Herceptin-based therapy prior to surgery for HER2+ early breast cancer.

Take a closer look at PERJETA + Herceptin-based therapy following surgery for HER2+ early breast cancer.

Understand how PERJETA + Herceptin-based therapy is given and possible side effects.

Discover information and resources to help you have an informative conversation with your doctor.